Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 55.47% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 55.47% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 24.95% from the prior year.
• Other Non-Current Assets grew to $2.4 million in Q1 2026 per RIGL's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.0 million in Q3 2023 and bottomed at $403000.0 in Q2 2022.
• The 5-year median for Other Non-Current Assets is $1.5 million (2024), against an average of $2.2 million.
• Across the five-year window, Other Non-Current Assets soared 923.97% in 2023 and sank 75.49% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $640000.0 in 2022, then surged by 377.34% to $3.1 million in 2023, then sank by 50.02% to $1.5 million in 2024, then rose by 24.95% to $1.9 million in 2025, then grew by 23.53% to $2.4 million in 2026.
• Per Business Quant, the three latest RIGL Other Non-Current Assets figures stand at $2.4 million (Q1 2026), $1.9 million (Q4 2025), and $1.2 million (Q3 2025).